The US Senate recently passed the US Food and Drug Administration (FDA) Safety and Innovation Act. According to an article on Politico, “The $6.4 billion, five-year reauthorization of FDA-industry user fee agreements partially funds the agency’s review of drugs and medical devices, which would have expired at the end of September without action. Previous user fee authorizations have been contentious affairs.”

Read the entire article here.